THOROFARE, N.J., Aug. 14, 2018 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (`Akers Bio` or the `Company`), a developer of rapid health information technologies, reports its financial results for the three months and six months ended June 30, 2018. A Form 10-Q containing the full financial statements is available for viewing on the Company`s website at www.akersbio.com or www.sec.gov. Q2 & H1 Financial Summary: Q2 total revenue $526,601 (Q2 2017: $1,072,861) Revenue from flagship PIFA Heparin PF/4 Rapid Assay products decreased by 17% to $356,082 (Q2 2017: $426,747), but increased by 37% against the first quarter of 2018 - the Company continued to experience lower...
|
